Want to see TSE:HBP full AI Analyst Report?
Helix BioPharma (HBP) AI Stock Analysis
Top Page
Helix BioPharma
(TSX:HBP)
The overall score reflects a highly speculative biotech profile dominated by weak fundamentals: no revenue, recurring multi-million-dollar losses, and structurally negative cash flow despite a cleaner, low-debt balance sheet. Technical indicators show a sharply extended, overbought and volatile share price, which adds near-term risk rather than durable support. Valuation offers little current downside cushion, with a negative P/E and no dividend yield, making the stock heavily dependent on future R&D and clinical outcomes.
Helix BioPharma (HBP) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 75.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,650
- Price to Earnings (P/E)
- -22.5
- Beta (1Y)
- 2.51
- Revenue Growth
- ―
- EPS Growth
- 54.45%
- Country
- Canada
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Helix BioPharma Business Overview & Revenue Model
Company Description
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Helix BioPharma’s operations have typically not been driven by recurring product sales; instead, its funding and potential revenue sources generally come from capital raising (e.g., equity financings), a...
Helix BioPharma Financial Statement Overview
Summary
Financial performance is very weak: Helix BioPharma has no revenue, large and persistent net losses, and consistently negative operating and free cash flow, partially offset by a recently strengthened, low-leverage balance sheet.
Income Statement
10Very NegativeBalance Sheet
40NegativeCash Flow
18Very Negative| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -5,000 | -10.00K | -14.00K | -13.00K | -12.00K | -173.00K |
| EBITDA | -3.08M | -5.21M | -9.38M | -6.31M | -6.03M | -9.44M |
| Net Income | -3.32M | -5.21M | -9.26M | -6.29M | -6.08M | -7.91M |
Balance Sheet | ||||||
| Total Assets | 21.38M | 18.80M | 1.49M | 1.03M | 3.73M | 4.07M |
| Cash, Cash Equivalents and Short-Term Investments | 2.84M | 65.00K | 1.08M | 808.00K | 3.25M | 3.56M |
| Total Debt | 359.00K | 336.00K | 0 | 0 | 2.47M | 3.61M |
| Total Liabilities | 6.69M | 3.22M | 1.58M | 1.87M | 3.41M | 5.46M |
| Stockholders Equity | 14.69M | 15.59M | -90.00K | -844.00K | 319.00K | -1.39M |
Cash Flow | ||||||
| Free Cash Flow | -3.21M | -3.83M | -5.23M | -5.54M | -6.51M | -9.30M |
| Operating Cash Flow | -3.21M | -3.83M | -5.22M | -5.53M | -6.51M | -9.30M |
| Investing Cash Flow | 0 | 17.00K | -14.00K | -5,000 | 0 | 2.02M |
| Financing Cash Flow | 5.32M | 2.80M | 5.51M | 3.09M | 6.21M | 6.56M |
Helix BioPharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HBP, the sentiment is Negative. The current price of 0.99 is above the 20-day moving average (MA) of 0.95, below the 50-day MA of 1.31, and below the 200-day MA of 1.64, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 45.56 is Neutral, neither overbought nor oversold. The STOCH value of 60.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HBP.
Helix BioPharma Peers Comparison
Overall Rating
- TSE:HBP45Neutral
TSE:MDNA43Neutral
TSE:ARCH40Underperform
TSE:MSCL39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:HBP | 45Neutral | CAD 75.61M | -22.50 | -21.54% | ― | ― | 54.45% |
| TSE:MDNA | 43Neutral | CAD 35.32M | -2.06 | -360.29% | ― | ― | -33.27% |
| TSE:ARCH | 40Underperform | CAD 56.38M | -19.53 | 74.79% | ― | ― | -15.53% |
| TSE:MSCL | 39Underperform | CAD 202.40M | -3.45 | -72.67% | ― | ― | -6.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:HBP | Helix Biopharma Corp. | 0.99 | -1.12 | -53.08% | |
| TSE:MSCL | Satellos Bioscience Inc. | 9.54 | 0.18 | 1.92% | |
| TSE:ARCH | Arch Biopartners | 0.83 | -0.19 | -18.63% | |
| TSE:MDNA | Medicenna Therapeutics | 0.46 | -1.04 | -69.67% | |
| TSE:METX | ME Therapeutics Holdings, Inc. | 1.10 | -4.25 | -79.44% | |
| TSE:ONCO | Onco-Innovations Ltd. | 1.47 | 0.00 | 0.00% |
Helix BioPharma Corporate Events
Helix BioPharma Taps Veteran Oncologist Markus Loeffler as CMO for Next Clinical Phase
PositiveHelix BioPharma Corp. is a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, with a focus on underserved patient populations. Its pipeline is led by L-DOS47, an antibody-enzyme conjugate being advanced as a co...
Helix BioPharma Reshapes Board to Align with Oncology Growth Strategy
PositiveHelix BioPharma Corp., a Vancouver-based clinical-stage oncology firm developing novel cancer therapies, has adjusted its board composition following its recent strategic expansion of pipeline assets. The move comes as the company continues to advanc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 26, 2026